For research use only. Not for therapeutic Use.
Lidorestat is a potent and selective aldose reductase inhibitor used in research on diabetic complications. Aldose reductase is an enzyme involved in the polyol pathway, where excess glucose is converted into sorbitol, leading to oxidative stress and tissue damage. By inhibiting this enzyme, lidorestat helps prevent the accumulation of sorbitol and related cellular damage, particularly in tissues like nerves, eyes, and kidneys, which are vulnerable in diabetic patients. Lidorestat has shown promise in reducing complications such as diabetic neuropathy, retinopathy, and nephropathy, making it a valuable tool for developing therapies targeting diabetes-related complications.
| Catalog Number | I007667 |
| CAS Number | 245116-90-9 |
| Synonyms | 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid |
| Molecular Formula | C18H11F3N2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25) |
| InChIKey | KYHVTMFADJNSGS-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=CN2CC(=O)O)CC3=NC4=C(C(=CC(=C4S3)F)F)F |
